AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A stable ~~immunoglubulin~~immunoglobulin preparation, wherein the preparation comprises immunoglobulin, a stabilizer comprising proline, ~~and~~ wherein the preparation has a pH of about 4.2 to about 5.4, and wherein the preparation does not comprise nicotinamide.

2-3. (Cancelled)

4. (Previously presented) The preparation of claim 1, wherein proline is L-proline.

5. (Currently amended) The preparation of claim 1, wherein said preparation has a pH of about 4.5 to about 5.2.

6. (Currently amended) The preparation of claim 5, wherein said preparation has a pH of about 4.6 to about 5.0.

7. (Currently amended) The preparation of claim 1, wherein the ~~final~~ concentration of proline in the preparation is at least 0.2 M.

8. (Currently amended) A stable immunoglobulin preparation, wherein said preparation comprises immunoglobulin, a stabilizer comprising proline, ~~and~~ wherein the preparation has a pH of about 4.2 to about 5.4, and wherein the ~~final~~ concentration of proline in the preparation is ~~between~~ from 0.2 to 0.4 M.

9. (Currently amended) The preparation of claim 1 or 8, wherein the ~~final~~ concentration of proline is 0.25 M.

10. (Previously presented) The preparation of claim 1 or 8, wherein the immunoglobulin concentration of said preparation is from 5 to 25% w/v.

11. (Currently amended) The preparation of claim 10, wherein the immunoglobulin concentration of said preparation is from 15 to 20% w/v ~~for subcutaneous administration~~.

12. (Currently amended) The preparation of claim 10, wherein the immunoglobulin concentration of said preparation is from 6 to 15% w/v~~, for intravenous administration~~.

13. (Previously presented) The preparation of claim 12, wherein the immunoglobulin concentration of said preparation is from 8 to 12% w/v.

14. (Cancelled)

15. (Previously presented) The preparation of claim 1 or 8, wherein said preparation is an IgG, IgA or IgM preparation.

16. (Previously presented) A pharmaceutical composition comprising the immunoglobulin preparation of claim 1 or 8 and pharmaceutically acceptable additives.

17. (Cancelled)

18. (Withdrawn - currently amended) A method of stabilising immunoglobulin preparations, comprising providing an aqueous immunoglobulin solution and adding

proline, wherein the pH of the solution is adjusted to a pH of about 4.2 to about 5.4, and wherein the preparation does not comprise nicotinamide.

19. (Cancelled)

20. (Withdrawn) The method of claim 18, wherein the pH is adjusted to 4.8.

21. (Withdrawn - Currently amended) The method of claim 18, wherein the final concentration of the proline in the preparation is ~~adjusted to between~~ from 0.2 to 0.4 M.

22. (Cancelled)

23. (Previously presented) A pharmaceutical composition comprising the immunoglobulin preparation of claim 1 and pharmaceutically acceptable additives.

24. (Withdrawn - currently amended) A method of decreasing aggregate formation and/or of decreasing colouring of immunoglobulin preparations, comprising providing an aqueous immunoglobulin solution and adding ~~one or more stabilisers chosen from non-polar amino acid~~ proline, wherein the pH of the solution is adjusted to a pH of about 4.2 to about 5.4.

25. (Withdrawn - Currently amended) The method of claim ~~25~~24, wherein the pH is adjusted to 4.8.

26. (Cancelled)

27. (Withdrawn - Currently amended) The method of ~~claim 26~~ claim 24, wherein the proline concentration is adjusted to ~~between~~ from 0.2 to 0.4 M.

28. (Currently Amended) The preparation of claim 1 or 8, wherein the ~~final~~ concentration of proline in the preparation is ~~between~~ from 0.2 to 0.3 M.

29. (New) The preparation of claim 15, wherein the preparation is an IgG preparation.

30. (New) The preparation of claim 29, wherein the concentration of IgG in the preparation is 8-12% w/v.

31. (New) The preparation of claim 30, wherein the concentration of IgG in the preparation is 10% w/v.

32. (New) The preparation of claim 29, wherein said preparation has a pH of about 4.6 to about 5.0.

33. (New) The preparation of claim 29, wherein said proline is L-proline, and the concentration of L-proline in the preparation is from 0.2 to 0.3 M.

34. (New) The preparation of claim 29, wherein the preparation is a liquid preparation and has not been subject to lyophilization.

35. (New) The preparation of claim 1 or 8, wherein the preparation is an IgG preparation, the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.4 M, and wherein the concentration of IgG in the preparation is 6-15% w/v.

36. (New) The preparation of claim 35, wherein the preparation is a liquid preparation that has not been subject to lyophilization.

37. (New) The preparation of claim 1 or 8, wherein the preparation is an IgG preparation, the preparation has a pH of about 4.6 to about 5.0, the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.3 M, and wherein the concentration of IgG in the preparation is 8-12% w/v.

38. (New) The preparation of claim 37, wherein the preparation is a liquid preparation that has not been subject to lyophilization.

39. (New) The immunoglobulin preparation of claim 1 or 8, wherein the preparation is an IgG preparation, the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.4 M, and wherein the concentration of IgG in the preparation is 15-20% w/v.

40. (New) The preparation of claim 39, wherein the preparation is a liquid preparation that has not been subject to lyophilization.